AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AstraZeneca, in collaboration with Parexel, is conducting a Phase III study titled LATIFY to evaluate the efficacy and safety of ceralasertib plus durvalumab compared to the standard treatment of docetaxel in patients with advanced non-small cell lung cancer (NSCLC) who have not responded to prior anti-PD-(L)1 therapy and platinum-based chemotherapy. This study is significant as it explores new treatment combinations for a challenging patient population.
The study tests two interventions: the experimental combination of ceralasertib, an oral drug, and durvalumab, an intravenous infusion, against the active comparator, docetaxel, a standard intravenous chemotherapy treatment. The goal is to determine if the combination therapy can improve patient outcomes.
This randomized, open-label study uses a parallel assignment model with no masking. It aims to treat patients, focusing on comparing the new combination therapy to the standard care of docetaxel.
Key dates for the study include its start on September 15, 2022, with an estimated completion date in July 2025. The study is currently active but not recruiting, indicating that patient enrollment is complete, and the focus is now on data collection and analysis.
The outcome of this study could significantly impact AstraZeneca’s market position, potentially boosting investor confidence if the results are positive. The study’s progress is closely watched by competitors and investors, given the high stakes in the oncology market.
The study is ongoing, with updates available on the ClinicalTrials portal.